Pharma companies need to take greater ownership to make sure data quality and governance is accomplished - and it is important to keep in mind the ethics of AI use will remain front and centre for the pharma industry.
In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.
Denmark says it is poised to revolutionize its technological landscape through a collaboration with multinational corporation NVIDIA, aimed at establishing a national center for AI innovation.
Patrick Hughes, co-founder and chief commercial officer of Cluepoints and OSP caught up for an in-person discussion during SCOPE 2024 to find out what developments the company had been working on and how they are benefiting from using AI.
In the fast-evolving landscape of clinical trials, technological advancements play a vital role in streamlining processes, enhancing efficiency, and ultimately improving patient outcomes.
Cresset, a leading provider of integrated in silico solutions for drug discovery, announced last month (February 21) a global collaboration with Enamine, one of the front providers of chemical building blocks and drug discovery services.
Creating artificial intelligence to understand medical conditions, and not just the English language, sounds far-fetched, but this is what one CEO is achieving with an impressive foundational innovation.
By ArisGlobal's new GenAI council sitting for first time this month
Life sciences technology company ArisGlobal, has announced the formal charter for the new generative AI Council, which will sit for the first time this month in a bid to advance life sciences innovation.
Always the buzz theme at pharma conferences, the subject of artificial intelligence (AI) continues to crop up more and more frequently. Naturally with more and more people using it for work, new regulations on data use and management are starting to appear....
WNS supports the research and brand teams of more than 30 life sciences companies. The company believes its comprehensive pharma market research capabilities help clients in assimilating information from various data sources.
Clinical data management is a vital phase in clinical research, that should lead to the generation of high-quality, reliable, and statistically sound data from clinical trials.
Science and technology giant, Merck, has launched its first software-as-a-service (SaaS) platform that it says bridges the gap between virtual molecule design and real-world manufacturability.
Today, world-leading generative artificial intelligence (AI) company for life sciences, Yseop, is celebrating its involvement in more than 150 clinical trials with pharma giants around the world.
OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.
Advanced tech company, PhaseV, has raised $15 million in funding that it says it will use to ‘push the boundaries of machine learning for clinical trial optimization’.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Drug discovery will benefit from a virtual artificial intelligence (AI) expert thanks to Opportunity Pharma and OpenEye, Cadence Molecular Sciences joining forces.
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
The US Food and Drug Administration (FDA) has today (July 31) given clearance via its 510(k) process to one of the artificial intelligence solutions cleared for colonoscopy.
Helmholtz Munich, part of Germany’s biggest research organization, the Helmholtz Association, alongside DDN, the world’s largest data storage company have been selected as a winner of the 2023 AI Breakthrough Awards, for best AI-based solution for life...
With generative AI continuing to create a buzz, OSP took the opportunity to speak to Indegene, a digital-first, life sciences commercialization company that helps biopharmaceutical, emerging biotech and medical device companies develop products. Talking...
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
The company is using a ‘lab-in-the-loop’ process to advance the drug discovery process, and stated that opening a new lab space represents a step forward on its path to ‘transform drug discovery’.
Software that can enhance stroke patient outcomes by decreasing detection time and reducing disabilities is the first CE marked device that can help find large vessel occlusions (LVOs).
Research emerging from the University of Toronto found that using machine learning models was able to guide the design of long-acting drug formulations.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
Pfizer and CytoReason have been partnered on artificial intelligence and machine learning technologies for drug discovery and development since 2019. The latest deal brings the companies closer.
A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
The pharmaceutical company has enlisted the help of the AI and NLP tech specialist to streamline clinical study report generation and submission processes.
A leader from the neurobiomarker platform provider tells how use of ML and other advanced analytical tools can help make better use of complex information.
The institute will combine the university’s AI, ML, health science, engineering, genomics, and data capabilities to tackle health strategy and inequity.
Leaders from the R&D tech company weigh in on how use of artificial intelligence has grown, ongoing challenges to effective adoption, and what lies ahead.
An executive from the AI specialist discusses how recent advances have provided opportunities for industry professionals to champion new ways of thinking.
Two experts from the CRO discuss artificial intelligence, machine language processing, and other analytical tools that can be useful in data management.
An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
A leader from the IT consulting company makes the case for digitization and explains the potenial benefits of bringing an operation into the 21st century.
